Bridge Biotherapeutics said Monday that it has been officially invited to present at the 43rd J.P. Morgan Healthcare Conference in San Francisco, California, to be held from Jan. 13 to 16 in 2025.  

The company stated that its selection highlights the growing interest in its idiopathic pulmonary fibrosis (IPF) treatment candidate, BBT-877, and the increasing demand for large-scale licensing deals.

CEO Lee Jung-kue will introduce the company’s major R&D projects, including BBT-877, which is expected to lead to significant licensing agreements. He will also outline the company’s growth strategies, targeting key stakeholders and investors in the pharmaceutical and biotech industries.

In addition to the presentation, Bridge Biotherapeutics plans to hold discussions with global big pharmaceutical companies to explore potential licensing agreements and business development opportunities. The company noted that it has already signed confidentiality agreements with over half of the top 10 global pharmaceutical companies and is in active talks regarding the clinical progress and plans for BBT-877.

“We are seeing growing interest from multinational pharmaceutical companies in the clinical data of BBT-877, especially among the top 10 global big pharma companies,” said Lee. “We will aim to expedite the signing of significant global licensing deals through numerous business development meetings at the conference.”

BBT-877, currently in the later stages of a phase 2 clinical trial across North America, Europe, and the Asia Pacific, is expected to release topline data in April next year. More than 75 percent of the trial’s 98 participants have completed 24 weeks of treatment, with data collection expected to finish in the first quarter of 2025. 

“With an unmet medical need in idiopathic pulmonary fibrosis, the demand for new treatments offering lung function recovery with minimal side effects is rising, making this a key market for big pharma,” said a Bridge Biotherapeutics official.